Skip to main content
Kathleen Squires, MD, Infectious Disease, Philadelphia, PA

Kathleen Squires MD

HIV/AIDS Medicine, Mycobacterial Disease


W. Paul and Ida H. Havens Professor of Infectious Diseases

Join to View Full Profile
  • 1015 Chestnut StSte 1020Philadelphia, PA 19107

  • Phone+1 215-955-7785

  • Fax+1 215-955-9362

Dr. Squires is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Infectious Disease, 1985 - 1986
  • MCP-Hahnemann College of Medicine
    MCP-Hahnemann College of MedicineClass of 1981

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2000 - Present
  • PA State Medical License
    PA State Medical License 1983 - 2026
  • AL State Medical License
    AL State Medical License 1993 - 2000
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Infectious Disease
    American Board of Internal Medicine Infectious Disease

Publications & Presentations

PubMed

Journal Articles

  • Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naive Adults with Human Immun...  
    George J Hanna, Peter Sklar, Kathleen E Squires, Paul E Sax, Carey Hwang, Clinical Infectious Diseases

Press Mentions

  • What Does a Caregiver Need?
    What Does a Caregiver Need?December 1st, 2021
  • More People with HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study Shows
    More People with HIV Virally Suppressed on Doravirine Than Darunavir at 96 Weeks, Study ShowsAugust 20th, 2018
  • HIV: Hopeful Results of Doravirine vs Ritonavir-Boosted Darunavir at 96 Weeks
    HIV: Hopeful Results of Doravirine vs Ritonavir-Boosted Darunavir at 96 WeeksAugust 2nd, 2018
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: